• Executed definitive agreement with Shed, a leading U.S. DTC telehealth platform
• Agreement converts previously announced binding Term Sheet into a long-form commercial agreement
• Shed committed to support delivery of at least 150,000 ROXUS units in the first 12 months

LTR Pharma Limited has executed a definitive Telehealth Distribution Agreement with Shed Holdings LLC, a leading U.S. direct-to-consumer (DTC) telehealth platform. This agreement converts the previously announced binding Term Sheet into a comprehensive commercial agreement governing the planned U.S. commercialization of ROXUS®. Shed will commercialize ROXUS through its dedicated men's health platform, Mavrox, and its own site, providing a streamlined digital pathway to consultation and treatment for U.S. patients. Shed has committed to support the delivery of at least 150,000 ROXUS units during the first 12 months following Commercial Launch, reflecting confidence in patient demand. This agreement represents another major milestone in LTR Pharma's U.S. commercialization strategy as the parties progress toward Commercial Launch.

LTR Pharma and Shed will focus on completing the remaining implementation activities required to support Commercial Launch, with ROXUS already featured on the Mavrox platform and a patient waitlist established.